Valuation: Nutriband Inc.

Market Cap 37.81M 32.7M 30.54M 28.01M 52.69M 3.6B 53.53M 358M 141M 1.8B 142M 139M 5.96B P/E 2025
-8.39x
P/E 2026 -1.86x
Enterprise Value 33.48M 28.96M 27.04M 24.81M 46.66M 3.19B 47.4M 317M 125M 1.6B 126M 123M 5.28B EV / Sales 2025
41.1x
EV / Sales 2026 26.5x
Free-Float
43.12%
Yield 2025 *
-
Yield 2026 -
1 day+6.69%
1 week+9.12%
Current month+9.12%
1 month+2.64%
3 months-17.94%
6 months-28.51%
Current year-31.50%
1 week 2.8
Extreme 2.8
3.11
1 month 2.8
Extreme 2.8
3.29
Current year 2.8
Extreme 2.8
4.98
1 year 2.8
Extreme 2.8
8.63
3 years 1.53
Extreme 1.53
11.78
5 years 1.53
Extreme 1.53
12.86
10 years 0.86
Extreme 0.857142
43.54
Manager TitleAgeSince
Chief Executive Officer 35 31/12/2015
Chief Executive Officer 52 -
Director of Finance/CFO 77 01/09/2020
Director TitleAgeSince
Chairman 52 20/01/2022
Director/Board Member 48 30/06/2018
Director/Board Member 38 30/06/2018
Date Insider Type Main position Quantity % Market Cap.
31/01/25 Other

Founder

126,833 1.1420%
31/01/25 Option

Chief Financial Officer

212,837 1.9164%
20/03/24 Free

Chief Financial Officer

162,500 2.0745%
Change 5-day change 1-year change 3-year change Capi.($)
+6.69%+9.12%-56.38%-17.29% 37.81M
-0.14%+2.00%-18.36%-0.59% 187B
+1.44%+2.07%-4.47%+2.88% 112B
-1.40%+2.93%+15.11%+71.75% 61.15B
+0.65%+3.91%+37.08%+53.44% 54.39B
-0.12%+6.79%-5.77%-35.74% 48.17B
+2.08%+1.56%+10.93%-29.94% 31.98B
+2.09%-10.31% - - 30.91B
+1.57%+3.85%+47.20%-6.50% 24.92B
+2.45%+3.97%+0.52%+4.99% 23.14B
Average +1.53%+2.22%+2.87%+4.78% 57.28B
Weighted average by Cap. +0.53%+2.02%+0.50%+8.82%

Financials

2025 2026
Net sales 2.14M 1.85M 1.73M 1.59M 2.98M 204M 3.03M 20.28M 7.96M 102M 8.03M 7.86M 337M 2.04M 1.76M 1.65M 1.51M 2.84M 194M 2.88M 19.3M 7.58M 97.15M 7.65M 7.48M 321M
Net income -10.48M -9.07M -8.47M -7.77M -14.61M -998M -14.84M -99.35M -38.99M -500M -39.36M -38.5M -1.65B -8.23M -7.12M -6.65M -6.1M -11.47M -783M -11.65M -77.99M -30.61M -393M -30.9M -30.23M -1.3B
Net Debt -4.13M -3.57M -3.33M -3.06M -5.75M -393M -5.84M -39.1M -15.35M -197M -15.49M -15.15M -651M -4.33M -3.74M -3.5M -3.21M -6.03M -412M -6.13M -41.03M -16.1M -207M -16.26M -15.9M -683M
Logo Nutriband Inc.
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Employees
-
Date Price Change Volume
07/08/26 US$3.110 +6.69% 6,454
06/08/26 US$2.915 +1.22% 2,994
05/08/26 US$2.880 +1.05% 14,077
04/08/26 US$2.850 +1.42% 6,993
03/08/26 US$2.810 -1.40% 5,602
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.110USD
Average target price
15.00USD
Spread / Average Target
+382.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NTRB Stock